SCHEMBL5136139

SCHEMBL5136139

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1c(F)cccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
CYP3A4 P08684 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
C5AR1 P21730 1/20 0.36
PDE4B Q07343 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 1/20 0.36
CRHR1 P34998 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
LMNA P02545 1/20 0.35
BCL2L1 Q07817 1/20 0.35
BAK1 Q16611 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134752 0.97 C5AR1 (0.39) TSHRALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5072419 0.95 CRHR1 (0.36) TSHRALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5137176 0.94 C5AR1 (0.37) TSHRALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5136698 0.93 ALDH1A1 (0.39) TSHRALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5134701 0.93 KDM4E (0.39) TSHRALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5134964 0.93 P2RX7 (0.40) ALDH1A1MEN1KMT2ASMN1; SMN2CRHR1
SCHEMBL5074878 0.90 TSHR (0.42) TSHRALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5134866 0.90 TSHR (0.42) TSHRALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5136067 0.89 KDM4E (0.41) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5135045 0.89 C5AR1 (0.38) TSHRALDH1A1KDM4ECYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed